Bioerodible polyanhydrides for controlled drug delivery

• US 4,906,474 A
• Filed: 05/21/1984
• Issued: 03/06/1990
• Est. Priority Date: 03/22/1983
• Status: Expired due to Term

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Leong, Kam, Linhardt, Robert J., Langer, Robert S., Rosen, Howard
• Primary Examiner(s): Teskin, Robin L.
• Application Number:
  US06/613,001
• Time in Patent Office: 2,115 Days
• Field of Search: 524/17, 524/21, 524/599, 424/19, 424/78, 424/424, 424/426, 424/466, 424/428, 424/78, 424/497, 604/890, 604/891, 604/892, 604/897
• US Class Current: 514/772.3
• CPC Class Codes: A61L 17/10 containing macromolecular materials
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: C08G 67/04 Polyanhydrides
• CPC Class Codes: C08L 73/02 Polyanhydrides

Abstract

A composition of matter suitable for implantation in the body to effect zero order drug release comprising a drug and a polymer of the formula: ##STR1## wherein R and R'"'"' can be the same or different and are hydrophobic organic linkages and n and m are integers of 1 or greater.

Claims

1. A composition of matter comprising a mixture of a therapeutic drug and a polymer of the formula:

##STR10## wherein R and R'"'"' can be the same or different and are hydrophobic organic linkages, the sum of n and m is between 10 and 106, and said polymer is polymerized from prepolymers formed from dicarboxylic acids, wherein the prepolymers are purified by recrystallization until the contaminants and degradation products present in the prepolymer are removed, said polymer being characterized by biocompatibility that results in minimal tissue irritation when implanted in vasculated tissue, and approximately zero order erosion and release rates of drug in vivo as a function of hydrolysis of the anhydride linkages in the polyanhydride.

2. The composition of claim 1 wherein R and R'"'"' are selected from the group consisting of an alkyl from 1 to 20 carbon atoms, p-carboxyphenoxymethane, benzyl, pyridine, and aromatic amino acids.

3. The composition of claim 2 wherein the amino acid is selected from the group consisting of phenylanine, tyrosine, tryptophan, and glycine.

4. The composition of claim 1 wherein the drug is selected from the group consisting of biologically active proteins, steroids, and antibiotics.